Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | IDE397: a novel MAT2A inhibitor in patients with solid tumors harboring MTAP deletions

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, talks on the trial design and rationale of an open-label, multicenter Phase I trial (NCT04794699) assessing the safety and efficacy of IDE397, a small molecule inhibitor of MAT2A, in patients with solid tumors with MTAP deletions. Initial enrollment included patients with lung, pancreatic and esophagogastric cancer, with the expansion cohort including additional patients with squamous lung and esophageal cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.